Ten research investigations

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does *Hypericum perforatum* exposure alter combined-pill metabolism or contraceptive efficacy, and can results from one formulation be generalized?  
**Primary evidence:** Hall et al. (2003), human PK trial in 12 pill users, [PMID 14663455](https://pubmed.ncbi.nlm.nih.gov/14663455/): norethindrone oral clearance increased, ethinyl estradiol half-life decreased, and breakthrough bleeding occurred in 7/12 during co-use vs 2/12 in control; gonadotropin/progesterone measures were not significantly different. Pfrunder et al. (2003), human randomized clinical/PK study, [PMID 14616430](https://pubmed.ncbi.nlm.nih.gov/14616430/): more breakthrough bleeding and lower 3-ketodesogestrel exposure, **without observed ovulation** in the studied cycles. Will-Shahab et al. (2009), human PK study of **low-hyperforin Ze 117** in 16 volunteers, [PMID 19015839](https://pubmed.ncbi.nlm.nih.gov/19015839/): no clinically important PK interaction with the particular pill/extract combination studied.  
**Synthesis:** Evidence of interaction is clinically relevant but not equivalent to an observed pregnancy rate. Low-hyperforin PK null is an extract-specific result, **not** a class-wide safety exemption or proof of contraceptive protection.  
**Prohibited inference:** All preparations cause documented pregnancies; all low-hyperforin products are proven compatible with contraceptives; absence of measured ovulation in one short trial establishes no risk.  
**Potential edit after review:** Pair the clinical interaction warning with explicit extract and measured-outcome qualifiers; clinician/pharmacist review of possible contraceptive interactions, without generic dosing advice.  
**Status:** P0 candidate; source identity already represented in repository for PMID 14663455, so reconcile before any ledger admission.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Can licorice intensify thiazide-associated potassium loss?  
**Primary evidence:** A human randomized, **open-label crossover** study of 10 healthy volunteers compared licorice alone with licorice plus hydrochlorothiazide over two-week exposures, [PMID 19562574](https://pubmed.ncbi.nlm.nih.gov/19562574/). Potassium did **not** significantly change in the licorice-only phase; the combination reduced plasma potassium by 0.32 mmol/L, and 2/10 developed hypokalemia during the combined phase. Separate controlled exposure in adults with/without essential hypertension, [PMID 12574791](https://pubmed.ncbi.nlm.nih.gov/12574791/), found greater mean blood-pressure responses among those with hypertension; this was **not** a randomized placebo-controlled outcome trial.  
**Synthesis:** A small human physiological interaction signal with a clinically meaningful hypokalemia event; evidence does not yield a population incidence estimate or a universal amount of licorice that is safe. Exposure amount and glycyrrhizin content matter.  
**Null/caveat:** Licorice-alone null within 10-person crossover; lack of long-term outcome data.  
**Potential edit:** Explicit potassium-losing diuretic interaction and hypertension-risk note, separated from mechanistic pseudoaldosteronism explanation.  
**Status:** P0 safety-review candidate; no patient-level action or dosing recommendations.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Do source species and processing materially affect iodine exposure?  
**Primary evidence:** Teas et al. (2004), **analytical study, not a clinical trial**, assayed 12 dietary seaweed species and preparations, [PMID 15588380](https://pubmed.ncbi.nlm.nih.gov/15588380/). Reported iodine levels ranged from about 16 micrograms/g (nori) to above 8,165 micrograms/g in a particular processed kelp-granule sample. A U.S. multivitamin **label survey**, [PMID 30266075](https://pubmed.ncbi.nlm.nih.gov/30266075/), documented that kelp was used as iodine source for some prenatal products; this survey read labels and **did not chemically verify actual contents**.  
**Synthesis:** The botanical group, preparation, serving mass, and processing create an exposure-identification problem. The seaweed-food assay **cannot** be misrepresented as a measured distribution across current kelp supplement bottles.  
**Null/gap:** Neither study establishes thyroid-disease incidence from a specific commercial product or measured versus labeled content in that product.  
**Potential edit:** Add species/product/lot verification gate and avoid generic kelp-to-iodine conversion or uniform per-serving amounts.  
**Status:** P0 product/identity hold; require current product laboratory evidence for numeric label-accuracy claims.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Can “red yeast rice 1200 mg” be treated as a reproducible lovastatin-equivalent exposure?  
**Primary evidence:** Cohen et al. (2017), **analytical study, not an RCT**, [PMID 28641460](https://pubmed.ncbi.nlm.nih.gov/28641460/): among 28 U.S. brands, monacolin K was undetectable in 2, and the other 26 varied more than 60-fold per 1,200 mg. Gordon et al. (2010), **product assay**, [PMID 20975018](https://pubmed.ncbi.nlm.nih.gov/20975018/): monacolin K varied substantially across 12 commercial preparations; four samples had elevated citrinin.  
**Synthesis:** Monacolin K is chemically identical to lovastatin, but measured potency is product/lot specific; labeled rice mass does not establish pharmacologically equivalent dose. Historical assay prevalence **must not** be portrayed as the current prevalence of citrinin contamination.  
**Null/gap:** No cardiovascular event, harm-incidence, or product-specific safety inference can be drawn from these cross-sectional assays.  
**Potential edit:** Flag statin-like pharmacology and variable strength alongside separate citrinin quality concern; require precise product claims to be lot-tested.  
**Status:** P0 risk + product-identity hold. Not a product endorsement.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does *Serenoa repens* improve urinary symptoms beyond placebo, including at higher exposure?  
**Primary evidence:** Bent et al. (2006), double-blind RCT of 225 men followed for one year, [PMID 16467543](https://pubmed.ncbi.nlm.nih.gov/16467543/): **no significant difference** in symptom score, urinary flow, prostate size, or related outcomes. Barry et al. (2011), multicenter double-blind RCT of 369 men up to 72 weeks with escalating extract exposures, [PMID 21954478](https://pubmed.ncbi.nlm.nih.gov/21954478/): mean urinary symptom improvement **was not superior to placebo**, including secondary endpoints.  
**Synthesis:** For these tested extracts and participant groups, robust null findings outweigh generic “clinically proven prostate relief” claims.  
**Limit:** Does not establish that every formulation or every endpoint in every population is identical.  
**Potential edit:** Prominently state placebo-controlled null results; separate traditional-use claims from clinically observed efficacy.  
**Status:** P1 candidate. PMID 21954478 already occurs in repository; no new-source claim until deduped.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does the trial justify equivalence to sertraline, or a demonstrated antidepressant effect?  
**Primary evidence:** Mao et al. (2015), 12-week **phase-II three-arm randomized placebo-controlled trial**, n=57, [PMID 25837277](https://pubmed.ncbi.nlm.nih.gov/25837277/). HAM-D, BDI, and clinician global change comparisons were **not significantly different across groups** (p=0.79, 0.28, 0.17 respectively). Adverse events were reported by 63.2% of sertraline recipients, 30.0% of rhodiola recipients, and 16.7% of placebo recipients.  
**Synthesis:** Fewer reported adverse events in a small trial cannot support a generalized claim of equivalent antidepressant efficacy or a proven favorable real-world benefit-risk profile. Non-significant between-group efficacy is an essential headline, not a footnote.  
**Null/gap:** Not powered as a noninferiority/equivalence study; one trial cannot establish replacement for prescription treatment.  
**Potential edit:** Correct overly positive depression claims; keep adverse-event observations explicitly trial-specific.  
**Status:** P1 source-reuse candidate: PMID 25837277 appears in pre-existing reconciliation/index materials.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Can a positive mild cognitive impairment (MCI) study support promises of instant focus for healthy young adults?  
**Primary evidence:** Mori et al. (2009), double-blind placebo RCT, **30 older adults with MCI**, [PMID 18844328](https://pubmed.ncbi.nlm.nih.gov/18844328/): cognition-scale scores improved vs placebo during a 16-week trial; small sample and population restriction apply. Surendran et al. (2025), **acute crossover RCT of 18 healthy adults aged 18–35**, [PMID 40276537](https://pubmed.ncbi.nlm.nih.gov/40276537/): **no significant effect on global cognitive or mood composite** after acute fruiting-body extract; a single pegboard-task result was positive.  
**Synthesis:** Longer-term MCI and acute young-adult studies differ in population, extract, duration and outcomes. “Proven instant mental clarity” is unsupported.  
**Null/gap:** No adequate clinical evidence from these two studies for ADHD treatment or neurological disease modification.  
**Potential edit:** Keep small-MCI positive finding beside younger-healthy acute null, with explicit route/extract identity.  
**Status:** P1; PMID 18844328 is already mentioned in repository materials, reuse rather than re-count.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Which improvements were measured, and were they better than placebo?  
**Primary evidence:** Hidese et al. (2019), double-blind randomized crossover trial of 30 healthy adults after four weeks, [PMID 31623400](https://pubmed.ncbi.nlm.nih.gov/31623400/): several stress, sleep, and executive measures improved, but comparisons must distinguish **within-arm changes from between-condition differences**; investigators included employees of the material supplier. Moulin et al. (2024), branded-product 28-day double-blind RCT with **15 participants per arm**, [PMID 38758503](https://pubmed.ncbi.nlm.nih.gov/38758503/): both placebo and active groups improved in perceived stress; **between-group salivary cortisol change was nonsignificant**; there were selected task/sleep signals, product-specific and small.  
**Synthesis:** These are small, short-duration studies; broad anxiety-disorder treatment and generalizable cognitive enhancement remain unestablished.  
**Null/gap:** Do not present within-arm PSS improvement as a proven active-versus-placebo benefit; no hard functional outcomes established.  
**Potential edit:** Differentiate outcome-specific signals, placebo response, conflicts, and brand/generic formulation.  
**Status:** P1; 2019 PMID already cited on live article and guide routes; correct claim framing, not duplicate source identity.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** How large is the randomized LDL change and what is the outcome ceiling?  
**Primary evidence:** Anderson et al. (2000), multicenter 26-week randomized cellulose-placebo comparison adjunct to a controlled diet, [PMID 10837282](https://pubmed.ncbi.nlm.nih.gov/10837282/): LDL **6.7% lower than placebo** at 24–26 weeks; other reported outcomes did not significantly differ. Davidson et al. (1998), 24-week randomized double-blind study of foods containing psyllium among **286 adults**, [PMID 9497178](https://pubmed.ncbi.nlm.nih.gov/9497178/): highest intervention group had LDL 5.3% below control at week 24; no significant HDL or triglyceride benefit.  
**Synthesis:** These studies support a modest **surrogate lipid marker** change in hypercholesterolemic adults under study conditions, not prevention of cardiovascular events or interchangeability with therapy.  
**Null/gap:** HDL/triglyceride null; no clinical-event endpoint in these studies.  
**Potential edit:** Express LDL delta with comparator and duration; avoid generic “protects your heart” as an endpoint claim.  
**Status:** P1 efficacy-precision candidate.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does cranberry juice consistently prevent recurrent UTI in women?  
**Primary evidence:** Barbosa-Cesnik et al. (2011), placebo-controlled RCT of **319 college women** with acute UTI, [PMID 21148516](https://pubmed.ncbi.nlm.nih.gov/21148516/): **no prevention benefit**, recurrence 20% cranberry versus 14% placebo. Stapleton et al. (2012), placebo-controlled RCT of **176 premenopausal women**, [PMID 22305026](https://pubmed.ncbi.nlm.nih.gov/22305026/): adjusted UTI hazard ratio 0.68 (95% CI 0.33–1.39; p=.29), **not significant**. Maki et al. (2016), 24-week randomized placebo-controlled trial with **373 women** and a specified beverage, [PMID 27251185](https://pubmed.ncbi.nlm.nih.gov/27251185/): investigator-diagnosed clinical UTI episodes 39 vs 67; adjusted rate ratio 0.61 (95% CI 0.41–0.91), but **time to culture-positive UTI did not significantly differ** (HR 0.97, p=.914). The Maki study had beverage-manufacturer support.  
**Synthesis:** Mixed trial results; distinguish clinically diagnosed episode counts, time to culture-verified UTI, studied populations and beverage identities. Preventive findings are **not treatment** for active infections.  
**Null/gap:** No inference that a generic retail capsule matches any studied juice; do not assert equivalence across cranberry PAC standardizations.  
**Potential edit:** A balanced prevention-only review with both positive and null trials, upfront outcome definitions.  
**Status:** P1 mixed-evidence candidate.

## Dedupe, publication and validation gates

- **Ten completed topic syntheses, not ten guaranteed novel PMIDs or ten production additions.** Original repo PMID spot checks found prior instances of: 14663455, 21954478, 25837277, 18844328, 31623400. Those are candidate **source reuses**; full canonical workbook and runtime source-key reconciliation is still required.
- **Evidence type is always labeled.** Product laboratory analyses, label surveys and controlled nonrandomized observations are **not** human efficacy RCTs; studies with randomization are scoped by extract, subject population, endpoint and duration.
- **Null results preserved.** In particular: no BPH benefit in two trials, no between-group significant depression change in the rhodiola trial, no acute global cognition or mood benefit in young-adult lion's mane trial, no cortisol group difference in the branded L-theanine trial, no consistent cranberry UTI benefit, and no established clinical-event benefits from psyllium trials.
- **Do not create automatic evidence-runtime ledgers or publish safety updates** from this intake. Independent scientific editorial confirmation, exact PubMed/DOI/title checks, duplicate-source reconciliation, product/formulation identity mapping, and relevant safety/approval gates are required before promotion. Historical waves are immutable; no reopening of quarantined records.
- **Follow-on acceptance tests:** source identity exact-match (PMID/title/year/DOI); target slug/entity existence; duplicate-source detection; extraction-vs-citation fidelity; formulation/route/outcome/null checks; independent approval; repository validation and green CI at exact PR head; after merge, production source/claim spot checks only if anything is promoted to public pages.
- **No synthetic ROI:** The dossier improves research precision but does not establish traffic, clicks, conversions, health outcomes, or deployed-site improvement. No clinical or commercial performance claim is authorized by this document.